Biotech Values

[caravon]

The GILD research chief is Norbert Bischofberger and he and his team are ambitious to keep pushing on to the next big challenge – and re-orientate their R&D focus when necessary.

Illustrating this point is a bold declaration from Bischofberger that Gilead has already ceased drug discovery in HCV and in HIV therapeutics – as there is nothing more to be done.

But Enanta is moving forward with HCV new drug development for "HCV failed patients" without clearly identifying the potential future market size. Assuming the present HCV treatment failure rate of 3% arketanf pre present annual HCV sale of ~$20B, a potential "HCV annual failure" annual market at ~$600M. It is not too bad for a company of ENTA size but, at best , ENTA can only field out such products no earlier that in 2020 (assuming they get off their butt).